University of Maryland School of Medicine Center for Integrative Medicine Annual Report for FY2015
MetadataShow full item record
Other TitlesCenter for Integrative Medicine Annual Report
Table of ContentsAt a Glance; Letter from the Director; Advancing the Science of Integrative Medicine; Humanizing the Hospital; Guiding Our Patients to Wellness; Creating Humanistic Healthcare Providers; Making Wellness Accessible; Finances.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/5407
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
Showing items related by title, author, creator and subject.
Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping ReviewLópez-Alcalde, Jesús; Yan, Yuqian; Witt, Claudia M.; Barth, Jürgen (Mary Ann Liebert Inc, 2020-07-01)Background: There is currently no effective treatment against coronavirus disease 2019 (COVID-19). The optimal selection of interventions targeting the virus is unknown. Therefore, evidence from randomized controlled trials (RCTs) to support specific treatment against COVID-19 is urgently needed. The use of Chinese herbal medicines (CHMs) might have a role in the treatment and symptomatic management of patients with COVID-19. It was aimed at providing an overview of the available evidence and ongoing trials concerning the effects of CHMs for the treatment of COVID-19. Methods: This is a narrative review of relevant studies. Searches were conducted to identify documents published till April 22, 2020. Electronic databases, evidence-based collections, websites of relevant organizations, and trial registries were consulted. Results: A total of 25 guidelines on the treatment of patients with COVID-19 were identified. Four guidelines provided recommendations on the use of CHMs; these guidelines were developed in China and South Korea and were based on the consensus of experts exclusively. The remaining 21 guidelines provided no guidance on CHMs. No finished RCTs of CHMs for the treatment of patients with COVID-19 was found. According to the evidence evaluated in this review, a Cochrane review of CHMs for severe acute respiratory syndrome and five uncontrolled observational studies of the effects of CHMs in patients with COVID-19, the effects of CHMs for COVID-19 are unknown. A total of 52 ongoing clinical trials of CHM interventions for the treatment of COVID-19 were found. These trials will be carried out mostly in China (n = 51). Forty (77%) of the ongoing trials will be randomized, whereas 12 (23%) have an unclear sequence generation procedure. Forty-seven trials (90%) will have a sample size <400 participants. Conclusions: To the authors' knowledge, only the Chinese and the South Korean guidelines recommend CHMs as a treatment option for patients with COVID-19. These guidelines base their recommendations on the consensus of experts. Clinical guidelines or health authorities from other countries do not provide advice on CHMs. Due to the absence of RCT, there is currently no reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. A high number of clinical trials of different herbal products are being currently conducted in China.
Ayurveda in Knee Osteoarthritis-Secondary Analyses of a Randomized Controlled Trial.Kessler, Christian S; Jeitler, Michael; Dhiman, Kartar S; Kumar, Abhimanyu; Ostermann, Thomas; Gupta, Shivenarain; Morandi, Antonio; Mittwede, Martin; Stapelfeldt, Elmar; Spoo, Michaela; et al. (MDPI AG, 2022-05-28)BACKGROUND: Ayurveda is widely practiced in South Asia in the treatment of osteoarthritis (OA). The aim of these secondary data analyses were to identify the most relevant variables for treatment response and group differences between Ayurvedic therapy compared to conventional therapy in knee OA patients. METHODS: A total of 151 patients (Ayurveda n = 77, conventional care n = 74) were analyzed according to the intention-to-treat principle in a randomized controlled trial. Different statistical approaches including generalized linear models, a radial basis function (RBF) network, exhausted CHAID, classification and regression trees (CART), and C5.0 with adaptive boosting were applied. RESULTS: The RBF network implicated that the therapy arm and the baseline values of the WOMAC Index subscales might be the most important variables for the significant between-group differences of the WOMAC Index from baseline to 12 weeks in favor of Ayurveda. The intake of nutritional supplements in the Ayurveda group did not seem to be a significant factor in changes in the WOMAC Index. Ayurveda patients with functional limitations > 60 points and pain > 25 points at baseline showed the greatest improvements in the WOMAC Index from baseline to 12 weeks (mean value 107.8 ± 27.4). A C5.0 model with nine predictors had a predictive accuracy of 89.4% for a change in the WOMAC Index after 12 weeks > 10. With adaptive boosting, the accuracy rose to 98%. CONCLUSIONS: These secondary analyses suggested that therapeutic effects cannot be explained by the therapies themselves alone, although they were the most important factors in the applied models.
Dr. Maureen Henderson, First Woman Chair of the Department of Preventive Medicine, 1971-1975Wink, Tara (2020-03-30)Dr. Henderson joined the faculty at the University of Maryland School of Medicine (UMSOM) in 1960 as an instructor. After joining the UMSOM faculty in 1960, she earned the title of Professor of Preventive Medicine in 1968 and was named Chair of the Department in December of 1971. At the time, she was the first woman to hold the title of Chair at Maryland’s medical school and one of few women chairs in schools of medicine around the country.